Mendus
Mendus AB is a Swedish clinical-stage biopharmaceutical company focused on developing immunotherapies for myeloid blood cancers. Its lead asset, vididencel, is being developed in multiple leukemia settings through the company’s subsidiaries and research collaborations, with operations centered in Stockholm and R&D activities in Leiden and Australia.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenueVididencel-based therapeutic development for myeloid malignancies.
Customers
Mendus does not sell a commercial product base in the traditional sense; its primary counterparties are clinical investigators, research institutions, and potential licensing or collaboration partners. The company’s programs are aimed at patients with AML and CML, while future value creation depends on partners that can support development, commercialization, or regional execution.
Hospitals and trial centers that enroll patients into vididencel studies in AML and CML.
Institutes such as ONJCRI that support trial execution, biomarker work, and clinical research.
Biopharma partners that may fund, co-develop, or commercialize the asset in selected territories or indications.
Specialist hematology-oncology centers that would use the therapy if it reaches commercialization.
Strategy
Mendus is focused on advancing vididencel through parallel clinical paths in AML and CML to broaden the asset’s potential use cases. The company also relies on collaborations and licensing options to extend development capacity and create future commercialization pathways.
AML is the core development area and a key proof point for the platform.
A second indication can broaden the addressable market and de-risk the asset.
External partners can provide capital, expertise, and commercialization reach.
Geography
Mendus is headquartered in Stockholm, Sweden, with R&D offices in Leiden, the Netherlands, and an Australian subsidiary. Its business is international by nature because clinical development, regulatory approvals, and future partnering can span multiple countries, even though the company currently reports no product revenue.
Risks
Mendus is exposed to the high failure rate and long timelines typical of clinical-stage biotech, where trial outcomes and regulatory decisions can materially change the value of a program. The company also faces financing risk, dependence on intellectual property, and reliance on external partners and approval/reimbursement regimes for any future commercialization.
- Insufficient financingImpact: CriticalLikelihood: High
The company states that available liquidity may not fund operations beyond the beginning of 2027.
Exposure: Clinical development continuity
- Clinical development riskImpact: HighLikelihood: High
Vididencel must show efficacy and safety in AML and CML trials before value can be realized.
Exposure: DIVA and VITAL-CML programs
- Regulatory and reimbursement riskImpact: HighLikelihood: Medium
Approval and reimbursement regimes can affect trial progression and future market access.
Exposure: Future commercialization
- Intellectual property dependenceImpact: HighLikelihood: Medium
The asset’s commercial value depends on patent and know-how protection.
Exposure: Vididencel platform
Accounting
Judgemental itemsManagement states liquidity may not be sufficient beyond early 2027 without additional capital.
Impact: Affects valuation of the company and interpretation of the financial statements
Issued warrants and employee incentives create non-cash expenses and equity movements.
Impact: Can distort period-to-period comparability of operating loss
The company notes fair values broadly correspond to carrying amounts, but estimates still matter.
Impact: Affects liabilities, trade payables, and financing-related disclosures
Mendus consolidates subsidiaries in Sweden, the Netherlands, and Australia using acquisition method accounting.
Impact: Influences consolidation balances and equity presentation
Similar listed companies
Publicly listed companies with a comparable business focus.
Healthier Choices Management Corp.
HCMC · Tobacco Products
Hong Yuan Holding Group
HGYN · Plastic Materials, Synth Resins & Nonvulcan Elastomers
HONG YUAN HOLDING GROUP is a U.S.-listed company in the plastics and synthetic resins value chain.
Valuence Merger Corp. I
VMCUF · Blank Checks
Valuence Merger Corp.
American Exceptionalism Acquisition Corp. A
AEXA · Blank Checks
American Exceptionalism Acquisition Corp.
Artificial Intelligence Technology Solutions Inc.
AITX · Services-Prepackaged Software
Amgen Inc
AMGN · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026